Neurotronic’s Neuviant Multiorgan Denervation Studied to Treat Type 2 Diabetes and Hypertension

November 17, 2025—Neurotronic, Inc. announced the first clinical outcomes of the NECTAR III and NECTAR IV trials evaluating the company’s Neuviant multiorgan denervation (MDN) system in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN).

The findings for this investigational therapy targeting multiple overactive sympathetic pathways via renal and hepatic denervation were presented at the TCT 2025 scientific symposium. Ajay J. Kirtane, MD, presented the results of NECTAR III. Professor Horst Sievert, MD, presented the results of NECTAR IV.

According to the company, both studies assessed the safety, performance, and efficacy of common hepatic and bilateral renal denervation in patients with T2DM and HTN.

NECTAR III enrolled patients who were diagnosed with both diseases and had either condition, or both, that was uncontrolled despite medications.

NECTAR IV required patients to have both diseases that were uncontrolled.

As outlined in Neurotronic’s press release, key outcomes presented for NECTAR III demonstrating the feasibility of MDN as a treatment for T2DM and HTN included the following:

• The 30-day procedural safety endpoint was met in 97.4% (37/38) of patients.
  • The one safety event was a complication in a renal accessory artery associated with placement of a guide catheter and resolved with percutaneous dilation and stenting.
  • The safety endpoint was defined as 30-day freedom from serious device or procedure-related complications (death, flow-limiting dissection, type 3 perforation, bleeding requiring transfusion, thromboembolization, clinically significant liver/renal dysfunction).
• The 6-month effectiveness was demonstrated through a reduction in HbA1c and 24-hour systolic ambulatory blood pressure measurements (sABPM).
  • Average HbA1c was reduced by -0.69% at 3 months and -0.53% at 6 months; 58% of patients improved by at least 0.5% at 3 months and 54% at 6 months.
  • Average sABPM was reduced by -6.6 mm Hg at 3 months and -5.5 mm Hg at 6 months; 58% of patients improved by at least 5 mm Hg at 3 months and 54% at 6 months.

The company reported that the NECTAR IV findings included the following:

• 85% (33/39) of patients received full treatment (multi-organ—hepatic and bilateral renal denervation).
• The primary procedural safety endpoint—defined as in NECTAR III—was met in 100% (39/39) of patients.
• Therapy effectiveness through 6-month follow-up was demonstrated through a reduction in HbA1c and 24-hour sABPM.
  • Average HbA1c was reduced by -1.03% at 3 months and -0.98% at 6 months; 78% of patients improved by at least 0.5% at 3 months and 74% at 6 months.
  • Average sABPM was reduced by -14.0 mm Hg at 3 months and -14.4 mm Hg at 6 months; 72% of patients improved by at least 5 mm Hg at 3 months, and 71% at 6 months; and most patients experienced more significant improvement with 64% improving by at least 10 mm Hg at 3 months and 62% at 6 months.
• In this population of patients with both diseases uncontrolled, Neuviant MDN was associated with excellent procedural safety and significant improvement in both blood glucose and blood pressure

Neurotronic’s United States pilot randomized controlled trial is scheduled to begin in 2026 with Dr. Kirtane serving as a National Principal Investigator, noted the company.